Advertisement
Advertisement
EXEL
Exelixis Inc
66.02
USDSponsored
-0.26
-0.40%
Oct 29, 15:26 UTC -4
Open
Exelixis Inc (EXEL) Earnings
EXEL Earnings Reports
Positive Surprise Ratio
EXEL beat 35 of 43 last estimates.
81%
Next Report
Today AMC
Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$659.26M
/$0.81
Implied change from Q2 26 (Revenue/ EPS)
+4.86%
/-1.22%
Implied change from Q3 25 (Revenue/ EPS)
+10.29%
/+17.39%
Exelixis Inc earnings per share and revenue
On Aug 05, 2026, EXEL reported earnings of 0.82 USD per share (EPS) for Q2 26, beating the estimate of 0.80 USD, resulting in a 2.28% surprise. Revenue reached 628.69 million, compared to an expected 648.67 million, with a -3.08% difference. The market reacted with a -7.94% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 0.81 USD, with revenue projected to reach 659.26 million USD, implying an decrease of -1.22% EPS, and increase of 4.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
DBV Technologies S.A. - ADR
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.70
Surprise
-670.08%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
FAQ
What were Exelixis Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Exelixis Inc reported EPS of $0.82, beating estimates by 2.28%, and revenue of $628.69M, -3.08% below expectations.
How did the market react to Exelixis Inc's Q2 2026 earnings?
The stock price moved down -7.94%, changed from $56.70 before the earnings release to $52.20 the day after.
When is Exelixis Inc expected to report next?
The next earning report is scheduled for Oct 29, 2026.
What are the forecasts for Exelixis Inc's next earnings report?
Based on --
analysts, Exelixis Inc is expected to report EPS of $0.81 and revenue of $659.26M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.